Novel constructs for thrombin inhibition.
Becker
Richard C
RC
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA. becke021@mc.duke.edu
D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D000925:Anticoagulants / Q000378:metabolism / Q000627:therapeutic use*; D001384:Azetidines / Q000378:metabolism / Q000627:therapeutic use; D001596:Benzylamines; D001777:Blood Coagulation / Q000187:drug effects; D003324:Coronary Artery Disease / Q000628:therapy; D015195:Drug Design; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009281:Naphthalenes / Q000378:metabolism / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D011355:Prodrugs / Q000378:metabolism / Q000627:therapeutic use*; D011422:Propionates / Q000378:metabolism / Q000627:therapeutic use; D033581:Stem Cell Transplantation; D013917:Thrombin / Q000037:antagonists & inhibitors*; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
C086910:(2S)-2-(4-(((3S)-1-acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphtyl)propanoic acid; D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D065427:Factor Xa Inhibitors; D009281:Naphthalenes; D011134:Polysaccharides; D011355:Prodrugs; D011422:Propionates; C446839:SR 123781A; C426686:ximelagatran; D006493:Heparin; D013917:Thrombin